ERASCA INC. - COMMON

Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

02 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments

25 May 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca Reports First Quarter 2022 Financial Results and Business Updates

12 May 2022 15:01:00 By Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities 2022 Healthcare Conference

03 May 2022 07:00:02 By Nasdaq GlobeNewswire

Erasca Appoints Jean Liu to its Board of Directors

27 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting

12 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway

06 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

24 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination

10 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting

08 Mar 2022 15:31:00 By Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day

03 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca Strengthens Leadership Team with Two Key Executive Appointments

18 Jan 2022 07:00:03 By Nasdaq GlobeNewswire

Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial

17 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Erasca Added to the Nasdaq Biotechnology Index

14 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference

16 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2021 Financial Results and Business Updates

10 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer

25 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021

27 Sep 2021 07:01:00 By Nasdaq GlobeNewswire

Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

22 Sep 2021 07:00:00 By Nasdaq GlobeNewswire